Jazz is an industry leader in treating sleep disorders and epilepsy, and in oncology it is investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. Within these therapeutic areas, the company is identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze